

In the Specification

Please replace paragraph 0020, on page 5, with the following paragraph:

[001] Referring now to Figure 1A, a block diagram of a system 1 implementing a clinical drug study (or trial) utilizing the techniques of the present invention includes a pool of study participants 10 who are eligible to participate in the clinical trial. The pool of eligible study participants 10 may include subjects who are deemed to be appropriate for the study (based on clinical and socio-demographic characteristics) and may possibly participate in the study. As is generally known, such possible study participant characteristics of interest are those characteristics which are relevant or important to the clinical trial being designed. It should be appreciated that those of ordinary skill in the art of clinical trial design will know how to select such characteristics. Information relevant to the study as well as information on the pool of eligible study participants may be stored in a storage device such as a database for example. ~~on the pool of eligible study participants may be stored in a storage device such as a database for example.~~

Please replace paragraph 0034, on page 9, with the following paragraph:

[002] The pool of study participants who complete the second phase of the study are arranged into six groups. A first group, designated $R-NRP_2$ corresponds to those study participants who did not respond to placebo in the first phase of the study but showed a response to placebo in the second phase of the study. A second group, designated $NR-NRP_2$, corresponds to those study participants who did not respond to placebo in the first phase of the study and did not show a response to placebo in the second phase of the study as well. A third group, designated $R-NRP_1$ corresponds to those study participants who did not respond to placebo in the first phase of the study but showed a response to active treatment in the second phase of the study. A fourth group, designated $NR-NRP_1$, corresponds to those study participants who did not respond to placebo in the first phase of the study and who did not show a response to active treatment in the second phase of the study. A fifth group, designated $[[R-NR_1]]$ $R-NRT_1$ corresponds to those study participants who did not respond to active treatment in the first phase of the study but showed a

response to active treatment (or placebo) in the second phase of the study. A sixth group, designated NR-NRT₁, corresponds to those study participants who did not respond to active treatment in the first phase of the study and did not show a response to active treatment (or placebo) in the second phase of the study.

Please replace paragraph 0058, on page 15, with the following paragraph:

[003] Once the first phase of treatment has been completed, the study participants in each of the groups 130a, 132a, 134a are separated into responders and non-responders. In group 130a, those study participants who quit smoking are considered responders (specifically, responders to treatment) and those study participants who do not quit smoking are considered non-responders (specifically, non-responders to treatment). Similarly, in groups 132a, 134a, those study participants who quit smoking are identified as responders (specifically, responders to placebo), while those study participants who do not quit smoking are identified as non-responders (specifically, non-responders to ~~treatment~~ placebo).